Clinical Report: The Real-world Impact of Suprachoroidal Triamcinolone Acetonide for Uveitic Macular Edema

Overview

This study evaluates the effectiveness and safety of suprachoroidal triamcinolone acetonide in treating uveitic macular edema (UME) in a real-world setting. Results indicate that a single injection can provide durable relief with manageable intraocular pressure (IOP) changes, even in patients at risk for elevated IOP.

Background

Uveitic macular edema is a challenging condition that can significantly impact vision and quality of life. The management of UME often involves corticosteroids, which carry a risk of elevated intraocular pressure, particularly in patients with a history of glaucoma. Understanding the real-world effectiveness and safety of suprachoroidal triamcinolone acetonide is crucial for optimizing treatment strategies in this patient population.

Data Highlights

Key Findings

• A single injection of suprachoroidal triamcinolone acetonide provides durable relief from UME.
• Most patients did not require additional treatments after the initial injection.
• IOP increases were low and manageable, even in patients with a history of glaucoma.
• Follow-up at regular intervals is recommended to monitor IOP changes.
• Suprachoroidal triamcinolone acetonide is well-tolerated in patients at risk for steroid-induced ocular hypertension.

Clinical Implications

Clinicians should consider suprachoroidal triamcinolone acetonide as a viable treatment option for UME, especially in patients with a history of glaucoma. Regular monitoring of IOP is essential to ensure patient safety and treatment efficacy.

Conclusion

Suprachoroidal triamcinolone acetonide is an effective and safe treatment for uveitic macular edema, offering long-lasting benefits with a low risk of significant IOP elevation. Its use should be considered in appropriate patient populations.

References

1. Retinal Physician, Suprachoroidal Injection of Triamcinolone Acetonide for Macular Edema in Retinal Vein Occlusion, 2018
2. Retinal Physician, Suprachoroidal Drug Delivery Technology, 2022
3. Retinal Physician, UVEITIS CORNER: Update on Topical and Local Steroid Treatments for Uveitis, 2023
4. Retinal Physician, Treatment of Uveitic Macular Edema, 2017
5. FDA, Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies, 2023
6. FDA Label for Suprachoroidal Triamcinolone Acetonide
7. Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide
8. Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies - PubMed